Mebita Pharmaceutical Private Limited, a active private limited company, was established on 27 August 2019 in East Delhi, Delhi, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24290DL2019PTC354287. Registered under ROC Roc Delhi. it is unlisted. It has an authorized capital of ₹2.50 M and a paid-up capital of ₹1.17 M.
It upholds a compliant status. Employing 48 professional, Its leadership includes Rupesh Kumar (Director), Nikhil Ranjan (Director), Narendra Nath Thakur (Managing Director). Past directors included Narendra Nath Thakur, Vanibhushan, Abhimanyu Kumar. It holds ₹1.26 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at B-52, Ground Floor West Guru Angad Nagar, Laxmi Nagar, East Delhi, Delhi, 110092.
U24290DL2019PTC354287
354287
27 August 2019
₹2.50 M
₹1.17 M
Roc Delhi
Unlisted
Active
Explore comprehensive insights into Mebita Pharmaceutical Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rupesh Kumar | Director | 27 Aug 2019 | Current |
| Nikhil Ranjan | Director | 27 Aug 2019 | Current |
| Narendra Nath Thakur | Managing Director | 27 Aug 2019 | Current |
| Vanibhushan | Director | 04 May 2022 | Current |
| Abhimanyu Kumar | Director | 28 Feb 2020 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 28 Feb 2020 | Past |
| Pramod Abcsdd | Additional Director | 28 Sep 2023 | Past |
| Pramod Abcsdd | Additional Director | 31 Dec 2020 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Mebita Pharmaceutical Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 437.44% increase. The company also saw a substantial improvement in profitability, with a 447.79% increase in profit. The company's net worth Soared by an impressive increase of 402.07%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Mebita Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹12,580,946.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 31 May 2023 | Hdfc Bank Limited | ₹0.68 M | Open |
| 29 Jul 2022 | Hdfc Bank Limited | ₹9.50 M | Open |
| 21 Oct 2021 | Others | ₹2.40 M | Open |
Explore comprehensive loan charge details -
Mebita Pharmaceutical has a workforce of 48 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Mebita Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mebita Pharmaceutical's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Mebita Pharmaceutical Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was completed.
Mebita Pharmaceutical Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Delhi. was recorded as a recent event.
Progress on A charge with Hdfc Bank Limited of Rs. 9.50 M registered on 29 Jul 2022 with Charge ID 100627973 was modified on 13 Feb 2024. was documented.
The activity A charge with Hdfc Bank Limited amounted to Rs. 0.68 M with Charge ID 100821330 was registered on 31 May 2023. was completed.
The activity A charge with Hdfc Bank Limited amounted to Rs. 9.50 M with Charge ID 100627973 was registered on 29 Jul 2022. was completed.
Vanibhushan was appointed as a Director was appointed as a Director on 04 May 2022 & has been associated with this company since 3 years 8 months . was recorded as a recent event.
The CIN of Mebita Pharmaceutical Private Limited is U24290DL2019PTC354287.
Mebita Pharmaceutical Private Limited is headquartered at B-52, Ground Floor West Guru Angad Nagar, Laxmi Nagar, East Delhi, Delhi, 110092.
Mebita Pharmaceutical Private Limited was incorporated on 27 August 2019.
The current directors of Mebita Pharmaceutical Private Limited are
The primary industry of Mebita Pharmaceutical Private Limited is Manufacturing.
Mebita Pharmaceutical Private Limited is unlisted.
The authorized capital of Mebita Pharmaceutical Private Limited is ₹2.50 M, and the paid-up capital is ₹1.17 M.
The compliance status of Mebita Pharmaceutical Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX